-
PBS Liposomes for Rigorous Macrophage Controls
2026-09-23
PBS Liposomes provide a non-depleting comparator that helps distinguish liposome uptake and handling effects from clodronate-driven macrophage loss. This guide presents paired in vivo and ex vivo workflows, practical control logic, and troubleshooting strategies for more interpretable macrophage depletion experiments.
-
Antimycin A4: Designing Interpretable Metabolic Assays
2026-09-22
Antimycin A4 is an ATP-citrate lyase inhibitor with a second mitochondrial target that can complicate biological interpretation. This article presents an evidence-led framework for separating lipid-biosynthesis effects from respiratory-chain effects and translates a synthetic chemistry study into practical assay-design principles.
-
(-)-JQ1 in BET Control Workflows
2026-09-22
(-)-JQ1 is a matched inactive control that helps distinguish BET bromodomain-dependent effects from vehicle, stress, and off-target responses. This guide translates findings from HPV-associated head and neck cancer research into practical dosing, assay-design, and troubleshooting workflows.
-
Caffeine N2379 for Reproducible Cell Assays
2026-09-21
Learn how Caffeine (SKU N2379) can support reproducible cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers mechanism, solvent compatibility, dose-response design, interpretation of approximately 2 mM IC50 data, and practical supplier-selection criteria.
-
DON Hepatotoxicity: Mitophagy and Nrf2 Disruption
2026-09-21
The reference study identifies a coupled mechanism of deoxynivalenol-induced liver injury: excessive PINK1/Parkin-mediated mitophagy damages mitochondria while suppression of the p62-Keap1-Nrf2 pathway weakens antioxidant defense. Mouse and AML-12 cell experiments, including mitophagy inhibition, PINK1 silencing, and p62 overexpression, provide a useful framework for dissecting toxin-associated hepatotoxicity.
-
Maraviroc (UK-427857) in CCR5 Research
2026-09-20
Maraviroc (UK-427857) provides a reversible pharmacological way to test CCR5 dependence in HIV-1 entry inhibition, viral tropism, and signaling assays. Its use can also extend into hypothesis-driven neuroinflammation modulation studies when paired with time-resolved immune and barrier readouts.
-
SGI-1027, DNMT1, and RB1 in Gastric Cancer
2026-09-19
The 2024 Discovery Medicine study links SGI-1027-mediated DNMT1 reduction with increased RB1 expression and suppression of gastric cancer cell growth, migration, invasion, and experimental metastasis. Its integrated cell and mouse experiments support a DNMT1–RB1 regulatory model while also highlighting the need for direct DNA methylation mapping and validation in additional gastric cancer systems.
-
(S,S)-Nanaomycin A and NEPC Plasticity
2026-09-19
DNMT3B emerges as a mechanistic bridge between enzalutamide resistance, neuroendocrine differentiation, and stemness in prostate cancer. This thought-leadership article translates the anchor study into a practical preclinical strategy for evaluating (S,S)-Nanaomycin A as a research tool for DNMT3B-dependent neuroendocrine prostate cancer.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-18
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat-derived IgG primary antibodies in ICC/IF, IHC, flow cytometry, and ELISA workflows. It should not be paired with non-goat primary antibodies or used in unvalidated applications without additional optimization and controls.
-
Dexamethasone in Inflammation Assay Design
2026-09-17
Dexamethasone is more than a glucocorticoid anti-inflammatory reference compound. This guide shows how to use its defined biology alongside a rosemary-root macrophage study to design better inflammation, neuroinflammation, stem-cell, and cancer-cell assays.
-
SGI-1027 DNA Methyltransferase Inhibitor Guide
2026-09-17
SGI-1027 is a non-nucleoside DNA methyltransferase inhibitor for connecting DNMT blockade with CpG demethylation, tumor suppressor gene reactivation, and apoptosis assays. This workflow-focused guide explains how to handle the compound, design concentration and time-course studies, and distinguish epigenetic effects from nonspecific loss of cell viability.
-
RG108 and Oct4: In Vivo Reprogramming in Mouse Brain
2026-09-17
This study compared RG108, BIX-01294, Bay K8644, and valproic acid (VPA) as enhancers of Oct4-driven pluripotency-marker induction in the mouse brain. Its central finding was that VPA, particularly when administered before Oct4 expression, produced the clearest transcriptional response, whereas RG108-containing combinations did not significantly alter the tested pluripotency or neural stem-cell markers in this model.
-
Carbapenemase Gene Spread in Enterobacter cloacae
2026-09-16
Chen et al. integrated gene localization, antimicrobial susceptibility, conjugation, mobile-element profiling, and strain typing to characterize carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The study found frequent blaNDM-1 carriage, high transferability of carbapenemase-encoding genes, and multidrug resistance, providing a practical framework for interpreting hospital transmission risk.
-
Nitroaromatic Nannocystin Targets AKT1 in Colorectal Cancer
2026-09-15
The reference study identifies a nitroaromatic nannocystin with nanomolar activity against colorectal cancer models and provides evidence that AKT1 contributes to its mechanism. By combining macrocycle synthesis, cell-based assays, patient-derived organoids, xenograft testing, RNA sequencing, molecular docking, and cellular thermal shift analysis, the work connects chemical innovation with in vivo efficacy.
-
Rucaparib in DNA Damage and Radiosensitization Research
2026-09-15
Rucaparib (AG-014699) provides a practical way to interrogate PARP1-dependent DNA repair, radiosensitization, and apoptosis in genetically defined cancer models. This workflow connects established DNA damage readouts with the newly described RNA Pol II degradation-dependent apoptotic response while clearly separating evidence from testable experimental hypotheses.